NeuroSense Reports Positive Preliminary Results from Alzheimer’s Biomarker Study

Jul 1, 2022 By MarketDepth

Biotechnology Headlines Healthcare Investing What's Hot

Cancer Research

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has reported results from its biomarker study conducted to evaluate the potential CogniC, NeuroSense’s drug for treatment of Alzheimer’s disease. NeuroSense’s biomarker study identified several biomarkers associated with AD, which indicate CogniC’s mechanism of action may be effective in targeting the pathways involved in the disease, such as miRNA dysregulation, lysosomal dysfunction, and impaired autophagy. Additionally, hallmarks of AD were detected, such as increased levels of amyloid-β (Aβ) and intracellular aggregates of tau protein among the panel of biomarkers evaluated.

“Having identified these promising biomarkers, which have the potential to be modulated by CogniC, we are now preparing to carry out a clinical proof-of-concept study in conjunction with a leading AD clinic. The study is expected to commence in 2023.”

NeuroSense CEO, Alon Ben-Noon

NeuroSense is conducting its AD biomarker study via utilization of Neuron-Derived Exosomes (NDE), a cutting-edge technology which allows one to observe key alterations in biomarkers found in the central nervous system in a non-invasive manner via collection of blood samples. Following further analysis, NeuroSense expects to share more detailed results on additional novel biomarkers that were evaluated in this study through scientific conferences and peer-reviewed publications.